Purpose: Marine triterpene glycosides that are physiologically active natural compounds isolated from sea cucumbers (holothurians) and sponges have antifungal, cytotoxic, and antitumor activities, whose specific molecular mechanisms remain to be elucidated. In this study, we examined if and through which mechanisms stichoposide C (STC) from Thelenota anax (family Stichopodidae) induces apoptosis in leukemia and colorectal cancer cells.
Introduction
Improvement of cure rates of leukemia and colorectal cancer require the identification of potentially new therapeutic agents. Acute myeloid leukemia (AML), which accounts for 80% of all acute leukemias in adults, is gradually increasing in incidence (1) , and although 60% to 80% of all treated AML patients achieve initial remission, the 5-year survival rate is only 15% in adults (2) . Standard AML therapy requires intensive combination chemotherapy (1) , which leads to significant treatment-related toxicity especially in elderly patients. Colorectal cancer is the third most common cancer in the world (3) and although new chemotherapeutic agents have improved prognosis (4), complete remission after surgery or chemotherapy remains difficult to achieve in advanced disease.
Marine triterpene glycosides are physiologically active natural compounds isolated from sea cucumbers (holothurians) and some sponges, which show a wide spectrum of biologic activities, including antifungal, antitumor, hemolytic, and cytostatic against various tumor cells (5, 6). In particular, stichoposides from sea cucumbers have antifungal, cytotoxic, and antitumor activities (7) through undefined molecular mechanisms. Stichoposide C (also known as stichloroside C1; STC; Fig. 1A ) is a quinovosecontaining hexaoside first isolated from the holothurian Stichopus chloronotus (8, 9) and later found in other Stichopodidae such as Thelenota ananas (10) . It was suggested that STC antitumor activity was mediated by membranotropic effects (7) .
Ceramide, which is involved in regulating many diverse cellular processes, including cell-cycle arrest, apoptosis, senescence, and stress responses (11) , is generated either by de novo synthesis or by sphingomyelin hydrolysis (12, 13) . There are several types, namely acid, neutral, or alkaline, of sphingomyelinases (SMase) that hydrolyze sphingomyelin in biologic membranes to release ceramide (11, 14) depending on their maximum activity at acid, neutral, or alkaline pHs, respectively (15) . Acid SMase and neutral SMase are involved in ceramide generation in response to apoptotic stimuli (16) (17) (18) . Anticancer agents increase ceramide levels, to variable extents, in all types of cancer cells (19) . In this context, the pharmacologic modulation of sphingolipid metabolism to enhance tumor cell ceramide represents a novel approach to cancer chemotherapy. Moreover, under conditions where the classical apoptotic pathway fails, intracellular generation of ceramide may function as part of an ancient backup system that enables caspase-independent programmed cell death (19) .
In this study, we explore the effects of Thelenota anaxderived STC on human leukemia and colorectal cancer cell proliferation, and the relationship to perturbations in signaling pathways. We show that STC induces apoptosis and ceramide production in leukemic cells and colorectal cancer cells. Our results suggest that ceramide generation, through activation of acid and neutral SMase, may play a role in STC-induced apoptosis and that STC might be a promising agent for the treatment of leukemia and colorectal cancer.
Materials and Methods

Cell preparations
Human leukemic HL-60, K562, THP-1, NB4 cell lines, human colorectal cancer cell lines (SNU-C4, , and murine colorectal cancer CT-26 cell lines were obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea) and cultured in RPMI1640 or Dulbecco's Modified Eagle's Medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. Human hematopoietic progenitor CD34 þ cells were purchased from STEM CELL Technologies and were cultured in Hematopoietic Progenitor Expansion Medium DXF with cytokine mix E (PromoCell). Human primary leukemic cells were obtained from 5 patients with AML at the Dong-A University Hospital, Busan, Korea. Informed consent was obtained from all patients before sample collection, according to the Institutional guidelines. Bone marrow mononuclear cells were isolated by Ficoll-Paque (Amersham Biosciences) density-gradient centrifugation. The percentage of blasts in the samples ranged between 75% and 91%. The purity of these cells in the samples was greater than 95%, which was confirmed by flow cytometric immunophenotyping using CD45 dim (þ), lineage-specific (myeloid) markers, and side scatter (SSC). These cells were cultured in RPMI1640 medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cultures were maintained in a humidified atmosphere of 95% air/5% CO 2 at 37 C.
Reagents STC was isolated according to the procedure published by Stonik and colleagues (8) . Briefly, specimens of the sea cucumber T. anax were collected at the Great Barrier Reef area, Australia, in September 1988, and were cut and extracted with ethanol at room temperature more than 1 week. The extract was evaporated at low pressure to dryness, dissolved in water, and loaded on a column with Teflon powder (Polychrom-1, Biolar, Latvia) fitted in alcohol and washed with water before loading. The salts and polar impurities were washed off with water and then the crude glycoside fraction was eluted with a mixture of acetone: water (1:1). The obtained eluate was concentrated by vacuum drying. The crude glycoside fraction was separated by repeated chromatography on a column with Si gel using chloroform:methanol:water (75:25:1) to yield STC. The purity of STC was confirmed by direct comparison of 1 H and 13 C NMR spectra and physical constants as well as by TLC on silica gel plates against a standard sample of the glycoside isolated from S. chloronotus. For experiments, STC was dissolved in dimethyl sulfoxide (DMSO). Annexin V was from BD Biosciences Clontech (Palo Alto). Antiprocaspase 8, antiprocaspase-3, antiprocaspase 9, and anticytochrome c antibodies were purchased from Santa Cruz Biotechnology. Antibody against PARP was purchased from Cell Signaling Technology. The anti-b-actin antibody was from Sigma. Z-Ile-Glu-Thr-Asp-fluoromethyl ketone (Z-IETD-FMK), Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-FMK), Z-Leu-Glu-His-Asp-fluoromethyl ketone (Z-LEHD-FMK), and Z-Asp (OCH 3 )-Glu (OCH 3 )-Val-Asp (OCH 3 )-fluoromethyl ketone (Z-DEVD-FMK) were from Sigma. L-buthionine-(S,R)-sulfoximine (BSO) was from Sigma. Unless stated otherwise, all other chemicals were purchased from Sigma.
Cell-cycle and apoptosis analyses
Cell-cycle analysis was carried out on propidium iodide (PI)-stained samples (20) ; whereas the extent of apoptosis was evaluated by annexin V-fluorescein isothiocyanate (FITC) and flow cytometry, as previously described (21) .
Translational Relevance
Triterpene glycosides from Stichopus chloronotus and Thelenota ananas are known to inhibit development of lymphocytic leukemia P388 through poorly characterized molecular mechanisms. This study found that stichoposide C (STC) from Thelenota anax induces apoptosis of leukemic and colorectal cancer cells via extrinsic and intrinsic pathways. The effect includes ceramide generation by activation of acid and neutral SMase by capase-8 activation and by glutathione depletion and reactive oxygen species production, respectively. STC also significantly reduced tumor size and upregulated ceramide expression without toxicity in a HL-60 xenograft and a CT-26 subcutaneous tumor models. These findings suggested consistency between in vitro and in vivo data and potential for STC as an anticancer drug for leukemia and colorectal cancer patients.
Measurement of mitochondrial membrane potential
Variations in mitochondrial membrane potential (Dj m ) during the induction of apoptosis were examined with DiOC 6 (Molecular Probes), as previously described (21) .
Separation of the cytosolic and mitochondrial proteins
Cytosolic and mitochondrial proteins were separated as previously described (20, 22) . In brief, cells treated with 0.1% DMSO or with STC for indicated times were collected and resuspended in mitochondrial isolation buffer and protease inhibitor cocktail (Boehringer Mannheim) supplemented with 10 mmol/L digitonin. Suspensions were incubated at 37 C for 5 minutes and centrifuged at 12,000 g for 15 minutes. The supernatant (cytosolic fraction) was collected for Western blotting. The pellets were resuspended in the radioimmunoprecipitation assay buffer with protease inhibitor cocktail, incubated at 4 C for 30 minutes with vortexing, and centrifuged at 15,000 rpm for 30 minutes. The supernatant (membrane fraction) was collected for Western blotting.
Separation of the cytosolic and membrane proteins
Cytosolic and membrane proteins were isolated using ProteoJET membrane protein extraction kit (Fermentas) according to manufacturer's instructions. Briefly, 5 Â 10 6 cells were pelleted by centrifugation for 5 minutes at 250 g, resuspended in 3 mL of ice-cold cell wash solution and recentrifuged. Ice-cold cell permeabilization buffer (1.5 mL) was added and incubated for 10 minutes at 4 C while continuously rocking. The permeabilized cells were centrifuged at 16,000 g for 15 minutes at 4 C. The supernatant (cytoplasmic protein extract) was collected for Western blotting. The pellets were resuspended in ice-cold membrane extraction buffer, incubated for 30 minutes at 4 C in the thermomixer, shaking at 1,400 rpm, and centrifuged at 16,000 g for 15 minutes at 4 C. The supernatant (membrane protein fraction) was used for Western blotting.
Western blot analysis
Cell lysis and Western blot analysis were conducted as described previously (21) . A total of 30 mg of protein was used for immunoblotting. b-actin was used as the loading control.
Immunofluorescence staining
Cells were fixed and permeabilized with 1% formaldehyde/methanol in PBS for 10 minutes at room temperature. After cells were washed, a series of antibodies was used as indicated, followed by FITC-or PE-conjugated goat antimouse and anti-rabbit IgG (Calbiochem) staining. The samples were then mounted using glycerol and analyzed by confocal microscope (Carl Zeiss LSM 510; Carl Zeiss) using a Â40 C-Apochromat objective. Negative control staining was conducted with secondary antibodies alone.
siRNA transfection
Predesigned and subjected to 300 V and 950 mF (Gene Pulser Xcell Electroporation System; Bio-Rad). After electroporation, cells were cultured in 10% FBS-supplemented RPMI1640 for 48 hours, then treated with 0.1% DMSO or STC for indicated times. These cells were then used for annexin-V staining, immunofluorescence staining, and Western blot analysis.
Assay of intracellular glutathione level
Total GSH levels in cells treated with 0.1% DMSO or STC for indicated times were measured by a glutathione assay kit (Sigma) according to manufacturer's instructions. In brief, the harvested cells were suspended in 3 volumes of the 5% sulfosalicylic acid solution of the packed cell pellet, frozen, and thawed twice. The precipitated proteins were pelleted by centrifugation at 10,000 g for 10 minutes at 4 C. Aliquots of the soluble supernatant were mixed with a working mixture [100 mmol/L potassium phosphate buffer, pH 7.0, with 1 mmol/L EDTA, glutathione reductase, and 5,5 0 -dithiobis-(2-nitrobenzoic acid) (DTNB) stock The extent of apoptosis was measured by flow cytometry after annexin V staining. These data represent the mean AE SD of 3 independent experiments. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 versus STC-treated cells. C, left; HL-60 and K562 cells were treated with 0.3 mmol/L STC or 0.5 mmol/L, respectively for 6 hours. The extent of apoptosis was measured by flow cytometry after annexin V staining. These data represent the mean AE SD of 3 independent experiments. ÃÃ , P < 0.01; ÃÃÃ , P < 0.001 versus solution] for 5 minutes and the diluted NADPH solution was added. The increase in absorbance at 412 nm was monitored to determine the amount of GSH in the sample. A reference curve was generated with 1 nmol of GSH standards. The concentration of GSH in the samples was calculated with the following equation:
nmole GSH/mL of sample ¼ DA 412 /min ðsampleÞ Â dilution factor/DA 412 /min ð1 nmolÞ Â volume:
Assessment of ROS production Reactive oxygen species (ROS) production was monitored by flow cytometry using 2 0 ,7 0 -Dichlorodihydrofluorescein diacetate (DCFH-DA) as described previously (21) . In the present study, cells were treated with STC for the indicated times and were washed twice with PBS to remove extracellular compounds. DCFH-DA (100 mmol/L) was added for an additional hour. Green fluorescence was excited using an argon laser and was detected using a 525-nm band-pass filter by flow cytometric analysis.
Establishment of HL-60 leukemia xenograft and mouse CT-26 subcutaneous tumors and experimental design
All animal procedures and care were approved by the Institutional Animal Care and Usage Committee of Dong-A University. To determine the in vivo activity of STC, viable HL-60 cells (2 Â 10 7 /100 mL PBS per mouse) and CT-26 cells (2 Â 10 6 /100 mL PBS per mouse), as confirmed by trypan blue staining, were injected into the right flank of 6-to 7-week-old female Balb/c nude mice and Balb/c mice, respectively (Orient Bio Inc.) as previously described (20) . When average subcutaneous tumor volume reached 60 to 100 mm 3 , mice were assigned into 2 treatment groups: (i) control and (ii) STC, given at a dose of 7.19 mg/kg via tail vein every 3 days. Control groups were treated with vehicle only. Tumor size was measured daily with a caliper (calculated volume ¼ shortest diameter 2 Â longest diameter/2). Mice were followed for tumor size and body weight and were sacrificed on the 14th or 21st day. Tumors were resected, weighed, and frozen or fixed in formalin and paraffin embedded for immunohistochemical studies.
Histology and immunohistochemical analysis
At the termination of experiments, tumor tissues were removed for histologic examination. Sections of tumor tissues were stained with hematoxylin and eosin, and immunohistochemistry was conducted with the DAKO EnVision Kit (DakoCytomation) as described previously (21) . Primary antibody against ceramide (1:10 dilution) was applied for 1 hour at room temperature. Next, the sections were incubated with EnVision reagent (DakoCytomation), which is a peroxidase-conjugated polymer backbone, carrying secondary antibody molecules. The sections were lightly counterstained with hematoxylin. After washing with PBS, VectorShield (Vector Laboratories, Burlingame, CA, USA) mounting medium was applied, and sections were cover slipped and imaged by ScanScope (Aperio Technologies, Inc.).
Statistical analysis
Statistical analyses were done with the SPSS 14.0 statistical package for Windows (SPSS). Data are expressed as mean values AE SD. One-way ANOVA was applied to determine whether there were significant differences in cell viability between STC-treated and control cells. Differences in tumor volumes between treated and control groups were evaluated using the unpaired Student's t test. Statistical significance was defined as P < 0.05.
Results
STC induces apoptosis of leukemic and colorectal cancer cells
To investigate the effect of STC on the growth of HL-60 cells, we used fluorescence-activated cell sorting analysis to analyze the cell-cycle profile. The flow cytometric analysis revealed no change except for an increase in representation of sub-G 1 phase (data not shown). These results suggest that STC inhibits proliferation of HL-60 cells by inducing apoptosis. To confirm an induction of apoptosis, HL-60 cells were treated with various concentrations of STC over a range of times and costained with PI and annexin V conjugated with FITC. STC treatment resulted in dose-and time-dependent increases in apoptotic cell proportions (Fig. 1B) . To evaluate whether the induction of apoptosis by STC is specific to HL-60 cells, or a more general effect, the same experiment was conducted in other leukemia cell lines (THP-1, K562, and NB4 cells) and colorectal cancer cell lines (CT-26, HT-29, and SNU-C4 cells). We also observed the induction of apoptosis by STC in additional cell lines and human primary leukemia cells, even though the effective concentration of STC used in each cell line was different ( Fig. 1C and D) . In contrast, the concentrations of STC that were used in this study (0.3-1.5 mmol/L) did not increase apoptosis of normal human hematopoietic progenitor cells compared with control, as further confirmed by annexin-V/ PI staining (Fig. 1D) .
STC activates both extrinsic and intrinsic pathways
There are 2 primary pathways for the activation of caspases-one triggered by receptor activation on the cell surface and the other by mitochondrial damage (23) (24) (25) .
The results described in the previous section prompted us to focus on the apoptotic signaling induced by STC in HL-60 and K562 cells and specifically on the cascade of caspase activation. Activation of caspases by STC was suggested by the cleavage of the caspase-3 substrate, PARP, and confirmed by the presence of cleaved caspase-3, caspase-8, and caspase-9 ( Fig. 2A) . To evaluate the functional involvement of caspases in STC-induced apoptosis, we used the pancaspase inhibitor (Z-VAD-FMK) and specific inhibitors of caspase-3 (Z-DEVD-FMK), caspase-9 (Z-LEHD-FMK), or caspase-8 (Z-IETD-FMK). Pretreatment with Z-VAD-FMK partially abolished STC-induced apoptosis (Fig. 2B) . In addition, pretreatment with Z-DEVD-FMK, Z-IETD-FMK, or Z-LEHD-FMK partly reversed STC-induced apoptosis (Fig. 2B) . These data suggest that a caspase-dependent mechanism may partially contribute to STC-induced apoptosis in HL-60 and K562 cells. To assess activation of the mitochondrial pathway by treatment with STC, we measured the mitochondrial membrane potential (Dj m ) and examined the expression of mitochondrial proteins in the cytosol by Western blot analysis. A marked loss of Dj m was observed in STC-treated HL-60 and K562 cells (Fig. 2C) . Loss of Dj m was accompanied by cytoplasmic release of cytochrome c, Smac/DIABLO, and AIF after treatment with STC (Fig. 2D ). These findings indicate that treatment of HL-60 and K562 cells with STC activates both the intrinsic and extrinsic apoptotic pathways.
STC generates ceramide through activation of acid and neutral SMase in leukemic and colorectal cancer cells To investigate the molecules upstream of STC-induced apoptosis, we assessed ceramide production using immunofluorescence microscopy. TNF-a increased the production of ceramide by activation of acid SMase and neutral SMase (26) and was used as a positive control. STC increased ceramide generation (Supplementary Fig. S1A ). To assess if acid SMase, neutral SMase, or ceramide synthase mediate STC-induced apoptosis, cells were incubated with desipramine (an inhibitor of acid SMase), GW4869 (an inhibitor of neutral SMase), or fumonisin B1 (an inhibitor of ceramide synthase) for 1 hour before they were incubated with STC. STC-induced apoptosis was partially blocked by pretreatment with desipramine or GW4869 (Fig. 3A) ; however, it was not blocked by pretreatment with fumonisin B1 (data not shown). The generation of ceramide by STC was also partially blocked by pretreatment with desipramine or GW4869 in HL-60 and K562 cells (Fig. 3B and C) . It was also observed in CT-26 and SNU-C4 cells ( Supplementary Fig.  S2A-S2D ). It is well established that activation of acid SMase is coupled with its translocation from intracellular compartments to the plasma membrane during cellular stress responses (27) (28) (29) (30) . Especially, the translocation of acid SMase by apoptin was observed by immunofluorescence microscopy (31) . Therefore, we investigated whether STC treatment caused a change in the subcellular location of acid SMase or neutral SMase by immunofluorescence microscopy using FITC-anticeramide antibody and PE-antiacid SMase or PE-antineutral SMase antibodies. We observed activation of acid SMase or neutral SMase by STC, which resulted in translocation of the enzymes to the plasma membrane (Fig. 3B and C) . In addition, the ceramide generation was observed as was in human primary leukemia cells ( Supplementary Fig. S1B and S1C) . We observed the translocation of acid SMase or neutral SMase into membrane using the membrane fractions and cytosol by Western blot analysis. Acid SMase or neutral SMase was increased in the membrane factions and decreased in the cytosol by STC treatment, as seen in TNFa-treated HL-60 cells (Fig. 3D) . In addition, the translocation of acid SMase or neutral SMase from cytosol to membrane fractions by STC was inhibited by desipramine or GW4869, respectively (Fig. 3D) . Taken together, these results suggest the generation of ceramide by STC, through activation of acid SMase or neutral SMase, may partly contribute to STC-induced apoptosis in leukemic and colorectal cancer cells.
To further confirm the essential role of acid SMase or neutral SMase activation in STC-mediated cell death, HL-60, K562, HT-29, and SNU-C4 cells were transiently transfected with 2 different siRNAs for acid SMase (ASM siRNA-1, ASM siRNA-2) or a neutral SMase (NSM siRNA-1, NSM siRNA-2) and compared with those transfected with the nonspecific control siRNA. Knockdown of acid SMase or neutral SMase was confirmed by immunofluorescence staining and Western blot analysis using the respective antibodies ( Fig. 4A-C) . The extent of apoptosis was monitored in transfected cells exposed to STC. Knockdown of acid SMase or neutral SMase by 2 different siRNAs partially protects cells from apoptosis induced by STC (Fig. 4D) . These findings indicate that activation of acid SMase or neutral SMase plays a functional role in the death of human leukemic and colorectal cancer cells treated with STC.
Activation of acid and neutral SMase by STC is independent from activation of Fas and caspase-8
To investigate the hierarchy of events accompanying STC-induced cell death, Fas, and caspase activation by STC was monitored in desipramine-pretreated or GW4869-pretreated HL-60 and K562 cells. Fas activation was not reversed by desipramine or GW4869 pretreatment (Supplementary Fig. S3A ). In addition, activation of caspase-9 or -3 was reversed by treatment with desipramine or GW4869; however, activation of caspase-8 was not blocked by either treatment (Supplementary Fig. S3B ). The same results were observed in cells transfected with acid SMase siRNA and neutral SMase siRNA (Supplementary Fig. S3C ). These results indicate that the activation of neutral SMase and acid SMase, in response to STC, occurs independently from Fas and caspase-8 activation or occurs downstream from Fas and caspase-8 activation.
Knockdown of Fas inhibits STC-induced apoptosis and acid SMase activation, but not neutral SMase activation
Our aforementioned data suggest that STC treatment activates Fas. To evaluate the functional significance of Fas activation in STC-induced apoptosis, cells were transiently 5 cells/well) were incubated with STC in the presence or absence of desipramine or GW4869 for 2 hours. Membrane and cytosolic fractions were prepared using ProteoJET membrane protein extraction kit and subjected to Western blot analysis as described in Materials and Methods using corresponding antibodies. Equal protein loading was ensured by showing uniform b-actin expression. The blot is representative of 5 separate experiments. TNF-a was used as a positive control. Right: K562 cells were treated with 0.5 mmol/L STC for indicated times. Membrane and cytosolic fractions were prepared using ProteoJET membrane protein extraction kits, and were subjected to Western blot analysis using corresponding antibodies, as described in Materials and Methods section. Equal protein loading was ensured by demonstrating uniform b-actin expression. The blot is representative of 5 separate experiments. K562 cells (1 Â 10 5 cells/well) were incubated with STC in the presence or absence of desipramine or GW4869 for 2 hours. Membrane and cytosolic fractions were prepared using ProteoJET membrane protein extraction kits and were subjected to Western blot analysis using corresponding antibodies, as described in Materials and Methods section. transfected with a Fas siRNA, and compared with those transfected with the nonspecific control siRNA. Knockdown of Fas was confirmed by Western blot analysis and immunofluorescence staining using antibodies against Fas (data not shown, Fig. 5A ) and the extent of apoptosis was monitored in transfected cells exposed to STC. Knockdown of Fas partially protected cells from apoptosis induced by STC (Fig. 5D ). These findings indicate that Fas activation plays a functional role in the death of human leukemic and colorectal cancer cells treated with STC. In addition, to investigate the hierarchy of events accompanying STC-induced cell death, activation of acid SMase or neutral SMase was monitored in Fas siRNA-transfected cells. Knockdown of Fas, which protects cells from STC-induced apoptosis, has little effect on STC-induced neutral SMase activation, but reduces STC-induced acid SMase activation ( Fig. 5B and C) . Activation of caspase-8 was also evaluated in the siRNA experiments and similar results were found (data not shown). These findings indicate that the activation of acid SMase, in response to STC, occurs downstream from activation of Fas and caspase-8.
GSH depletion and ROS production may contribute to STC-induced neutral SMase activation and apoptosis in leukemic and colorectal cancer cells A previous study showed that GSH inhibited in vitro neutral SMase from Molt-4 leukemic cells (32) . To investigate the effects of GSH on STC-induced apoptosis and neutral SMase activation, cells were treated with STC and then the levels of GSH and apoptosis were measured. STC treatment resulted in decreased GSH levels and STC-induced apoptosis was decreased by pretreatment with GSH and N-acetylcysteine (NAC), a precursor of GSH biosynthesis ( Supplementary Fig. S4A and S4B ). In addition, GSH and NAC pretreatment inhibited the activation of neutral SMase, but not the activation of Fas and acid SMase (Supplementary Figs. S5A-S5C and S6A-S6C). GSH pretreatment inhibited the activation of caspase-9 and caspase-3; however, it did not inhibit the activation of caspase-8 ( Supplementary Fig. S5D ). These results suggest that the depletion of GSH by STC occurs before activation of neutral SMase. We also examined the effect of BSO, an inhibitor of GSH biosynthesis, on STC-induced apoptosis and neutral SMase activation. As expected, BSO significantly increased STC-induced apoptosis and activation of neutral SMase in leukemic and colorectal cancer cells ( Supplementary Figs. S4B and  S6B) . Thus, these data are similar to previously reported ones showing that GSH inhibits the activation of neutral SMase (26) .
The depletion of GSH by STC raises the possibility that 1 or more oxidative injury-related mechanism of lethality may be involved. Thus, we measured ROS levels in HL-60, K562, HT-29, or SNU-C4 cells exposed to STC. STC induces the production of ROS in these cells (Supplementary Fig. S4C ). To investigate the functional relationship of ROS production by STC to cell death, cells were exposed to STC in the absence or presence of NAC or catalase. Coexposure of cells to NAC or catalase blocked STC-induced ROS production and essentially abolished apoptosis (Supplementary Fig. S4B and S4C) . Moreover, cells treated with STC plus NAC or catalase displayed a marked inhibition of neutral SMase activation and a partial recovery of GSH depletion ( Supplementary Figs. S4A and S6A-S6C). Thus, these data suggest that the depletion of GSH and the production of ROS by STC may interact reciprocally and that both occur upstream of neutral SMase activation.
Antitumor activity and generation of ceramide by STC in vivo
We observed the STC-induced apoptosis and the upregulation of ceramide in CT-26 cells as well as in human leukemia cells. Thus, we evaluated the ability of STC to inhibit tumor growth of cancer cells in a mouse HL-60 xenograft tumor model and CT-26 subcutaneous tumor model. As shown in Figs. 6A and C, STC significantly decreased tumor growth. The tumors from control mice showed the typical histologic appearance of leukemic and colorectal cancer cells (Fig. 6B and C) ; P < 0.01, respectively). The sections from STC-treated HL-60 xenograft tumors and CT-26 tumors showed cancer cells were markedly decreased, with apoptotic regions with infiltration of inflammatory cells. As expected, tumors from vehicle-treated control mice stained weakly for ceramide ( Fig.  6B and D) . In contrast, immunohistochemical analysis of tumors from STC-treated mice revealed upregulation of ceramide ( Fig. 6B and D) . These data are consistent with the in vitro findings. Mice treated with STC did not show signs of wasting (data not shown). We also assessed the toxicity of STC in Balb/c mice by checking the level of glutamate-oxaloacetate transaminase and glutamate-pyruvate transaminase. The dosage that we used in this experiment was safe based on the blood chemistry results (data not shown). These data suggest upregulation of ceramide parallels in part the antineoplastic activity of STC and that these effects on a major signal transduction pathway could be related to the mechanism of STC.
Discussion
Natural products have been recognized as an important source of therapeutically effective drugs, and their role in the prevention and treatment of cancer is becoming increasingly evident. Previous studies have shown that triterpene glycosides from S. chloronotus and T. ananas inhibit the development of lymphocytic leukemia P388 (33) . In this study, we showed that STC from T. anax negatively regulates cell proliferation by inducing apoptosis in leukemic and colorectal cancer cells. Until now, the molecular mechanisms underlying STC-induced apoptosis in these cell lines have been unknown. The present study shows that STC treatment activates extrinsic and intrinsic pathways of apoptosis. To confirm whether STC-induced apoptosis occurs through a caspase-dependent pathway, cells were treated with caspase inhibitors before the addition of STC. Caspase inhibitors partially reversed the induction of apoptosis by STC. These data suggest that STC-induced apoptosis occurs in part through a caspase-dependent pathway.
Ceramide has recently emerged as a novel second messenger to exert potent proapoptotic effects in a variety of cell types (34) . However, little is known of the functional role of ceramide in mediating STC-induced lethality in leukemia and colorectal cancer cells. Our data suggest that generation of ceramide, through activation of acid SMase and neutral SMase, may contribute to the lethality of leukemic and colorectal cancer cells. Similar to the findings in TNFainduced apoptosis (26), we found that STC-induced apoptosis requires activation of acid SMase and neutral SMase. Thus, we suggest that the action of STC may be related to TNFa production. However, we did not check the level of TNFa in this study. Future studies will be necessary to unravel the role of TNFa in STC-induced apoptosis.
Some reports have shown that ceramide molecules form ceramide-enriched membrane platforms, a prerequisite for signal amplification and induction of death via CD95 (27, 35) whereas other reports suggested that acid SMase activation results from that of caspase-8 (36) . To clarify whether caspase-8 activation by STC occurs through acid SMase activation, we conducted several experiments using siRNA transfection and chemical inhibitors. The activation of acid SMase by STC was found to be reversed by Fas siRNA knockdown. In addition, pretreatment with desipramine did not block the activation of Fas and caspase-8. On the basis of our observations, we suggest that STC leads to Fas activation followed by caspase-8 activation, finally resulting in acid SMase activation. Thus, we suggest that the primary action point of STC is a lipid raft of plasma membrane, as STC has strong membranotropic activity. However, the involvement of a lipid raft in STC-induced apoptosis was not examined in this study. Further studies are required to investigate whether lipid raft clustering is involved in STCinduced apoptosis.
Depletion of GSH has been observed in response to many inducers of apoptosis (37, 38) . Especially, TNFa causes a dramatic depletion of GSH, which is closely related to Figure 6 . STC inhibits the growth of mouse tumors and increases the production of ceramide in vivo. A, HL-60 cells (2 Â 10 7 cells/100 mL) were injected subcutaneously into Balb/c nude mice. After HL-60 cells formed palpable tumors, mice were randomized into 2 groups (n ¼ 5), and treatment was initiated. Mice were treated with vehicle control and STC (7.19 mg/kg) as described in the Materials and Methods. Tumor size was measured daily with a caliper (calculated volume ¼ shortest diameter 2 Â longest diameter/2). ÃÃ , P < 0.01; ÃÃÃ , P < 0.001, significantly different from respective control. B, top: hematoxylin-eosin staining. Stained sections were examined and photographed with a ScanScope (Aperio Technologies, Inc.). HL-60 leukemia xenografts from mice treated with STC showed apoptosis and extensive necrosis with phagocytes (Â200). Bottom: tumor tissues obtained from the above experiment on day 14 were subjected to immunohistochemistry using antibodies against ceramide. The sections were lightly counterstained with hematoxylin and photographed with a Scan Scope. HL-60 xenograft tumors from mice treated with STC showed a dramatic increase of ceramide (Â200). C, CT-26 cells (2 Â 10 6 cells/100 mL) were injected subcutaneously into the right flank. After CT-26 cells formed palpable tumors, mice were randomized into 2 groups (n ¼ 5), and treatment was initiated. Mice were treated with vehicle control and STC (7.19 mg/kg) as described in the Materials and Methods. Tumor size was measured daily with a caliper (calculated volume ¼ shortest diameter 2 Â longest diameter/2). ÃÃ , P < 0.01; ÃÃÃ , P < 0.001, significantly different from respective control. D, top: hematoxylin-eosin staining. Stained sections were examined and photographed with a ScanScope (Aperio Technologies, Inc.). CT-26 tumors from mice treated with STC showed apoptosis and extensive necrosis with phagocytes (Â200). Bottom: tumor tissues obtained from the above experiment on day 14 were subjected to immunohistochemistry using antibodies against ceramide. The sections were lightly counterstained with hematoxylin and photographed with a Scan Scope. CT-26 tumors from mice treated with STC showed a dramatic increase of ceramide (Â200).
activation of neutral SMase (37) . In this study, STC leads to GSH depletion, increased ROS production, neutral SMase activation, ceramide generation, and apoptosis. Replenishment of GSH prevents activation of neutral SMase and offers partial protection against STC-induced ROS production, ceramide generation, and eventual cell death. It was observed that BSO treatment increased STC-induced apoptosis, as well as ROS generation, and neutral SMase activation. It is usually assumed that GSH depletion reflects an intracellular oxidation, similar to our observations. In contrast, a previous study showed that GSH is directly exported from a cell undergoing apoptosis via activation of a transmembrane channel (38) . Our results are consistent with a previous report that GSH depletion functions in the activation of neutral SMase (37) .
We also observed the antitumor effect of STC in vivo and the upregulation of ceramide in a mouse HL-60 leukemic xenograft model and CT-26 subcutaneous tumor model. These results are consistent with the in vitro data. In addition, the lack of toxicity in a mouse model points to STC as a potential candidate for therapeutic use. These data suggest STC can be a possible anticancer agent for the treatment of leukemia and colorectal cancer.
In summary, our study provides the first evidence that STC induces apoptosis of leukemic and colorectal cancer cells via ceramide generation by activation of acid SMase following activation of caspase-8 and activation of neutral SMase from depletion of GSH and increased production of ROS. In addition, STC has antitumor activity in vivo without any toxicity. These results suggest STC may be of therapeutic importance in the treatment of human leukemia and colorectal cancer.
